

# 1 Maternal obesity, interpregnancy weight changes and congenital 2 heart defects in the offspring: a nationwide cohort study

3 Gitte HEDERMANN, MD\*<sup>1,2,3</sup>; Ida N THAGAARD, MD, PhD<sup>1,4</sup>; Paula L HEDLEY, PhD, MPH<sup>1</sup>; Lone  
4 KREBS, MD, DMSc<sup>5,6</sup>; Christian M HAGEN, MSc<sup>1</sup>; Thorkild I A SØRENSEN, MD, DMSc<sup>7,8</sup>; Michael  
5 CHRISTIANSEN, MD, FRCPath<sup>1,9</sup>; Charlotte K EKELUND, MD, PhD<sup>6,10</sup>

6

7 <sup>1</sup> Department for Congenital Disorders, Danish National Biobank and Biomarkers, Statens Serum  
8 Institut, Copenhagen, Denmark

9 <sup>2</sup> Department of Obstetrics and Gynecology, Copenhagen University Hospital, Rigshospitalet,  
10 Copenhagen, Denmark

11 <sup>3</sup> Department of Obstetrics and Gynecology, Slagelse Hospital, Denmark

12 <sup>4</sup> Department of Obstetrics and Gynecology, Nordsjællands Hospital, Denmark

13 <sup>5</sup> Department of Obstetrics and Gynecology, Copenhagen University Hospital, Amager and  
14 Hvidovre Hospital, Copenhagen, Denmark

15 <sup>6</sup> Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

16 <sup>7</sup> Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen,  
17 Denmark

18 <sup>8</sup> The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and  
19 Medical Sciences, University of Copenhagen, Copenhagen, Denmark

20 <sup>9</sup> Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

21 <sup>10</sup> Center of Fetal Medicine, Department of Obstetrics, Copenhagen University Hospital,  
22 Rigshospitalet, Copenhagen, Denmark

23

24 Disclosures: The authors report no conflict of interest

25

26 Funding: This study was supported by The Danish Children Heart Foundation (18-R109-A5193-  
27 26043), The A.P. Moller Foundation (19-L-0096), and Aase and Ejnar Danielsen's Foundation (19-  
28 10-0493). This research has been conducted using the Danish National Biobank resource  
29 supported by the Novo Nordisk Foundation. The funders had no role in study design, data  
30 collection and analysis, decision to publish, or preparation of the manuscript.

31

32 Paper presentation information: Part of the data has been presented at the 31st World Congress  
33 on Ultrasound in Obstetrics and Gynecology 2021 (Virtual, 15-17 October:  
34 <https://obgyn.onlinelibrary.wiley.com/doi/10.1002/uog.23862>) and 32nd World Congress on  
35 Ultrasound in Obstetrics and Gynecology 2022 (London, 16-18 September:  
36 <https://doi.org/10.1002/uog.25154>).

37

38 Corresponding author: Gitte Hedermann, Department for Congenital Disorders, Danish National  
39 Biobank and Biomarkers, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen, Denmark,  
40 phone: +45 2081 0261, e-mail: [gihc@ssi.dk](mailto:gihc@ssi.dk)

41

42 Word count: abstract (492 words); main text (2 848 words)

43 **Condensation**

44 Tweetable statement: The risk of fetal congenital heart defect is associated with high maternal  
45 BMI, and it may also be affected by a substantial weight gain between pregnancies.

46

47 Short Title: Maternal obesity and CHDs in the offspring

48

49 **AJOG at a Glance**

50 A. Why was this study conducted?

51 • None of the large cohort studies on the association between maternal BMI and congenital  
52 heart defects (CHDs) have included the proportion of CHDs that are identified in  
53 terminated pregnancies.

54 • No previous studies have investigated the association between interpregnancy weight  
55 changes and CHDs.

56

57 B. What are the key findings?

58 • Risk of CHDs became gradually higher with higher maternal BMI when including live births,  
59 stillbirths, abortions and terminated pregnancies.

60 • A trend was found between interpregnancy weight gain and risk of CHDs.

61

62 C. What does this study add to what is already known?

- 63       • The association between high maternal BMI and risk of CHDs are not caused by a lower  
64       detection rate of fetal CHDs in pregnant women with obesity.

65 **Abstract**

66 Background: Maternal obesity has been positively associated with increased risk of congenital  
67 heart defects in the offspring. However, none of the large studies have included the considerable  
68 proportion of congenital heart defects that are identified due to improvements in prenatal  
69 diagnostics and terminated in pregnancy. The mechanism behind the association is poorly  
70 understood, and a relation to interpregnancy weight changes is to be investigated.

71 Objectives: To evaluate the association between maternal obesity and congenital heart defects in  
72 the offspring when including all pregnancies and to investigate if interpregnancy weight change  
73 between the first and second pregnancy influences risk of fetal congenital heart defects.

74 Study Design: A nationwide cohort study of all singleton pregnancies in Denmark from 2008 to  
75 2018. All data on maternal and offspring characteristics were retrieved from the Danish Fetal  
76 Medicine Database. The database included data on postnatal diagnoses of congenital heart  
77 defects in live births and prenatal diagnoses of congenital heart defects from ultrasound  
78 examinations during pregnancy resulting in live birth, stillbirth, spontaneous abortion after  
79 gestational week 12 or termination of pregnancies after gestational week 12. As this cohort  
80 encompassed all pregnancies over a 10-year period, it was possible for women to experience  
81 multiple pregnancies. Congenital heart defects and severe congenital heart defects were grouped  
82 according to European Surveillance of Congenital Anomalies' definitions. Children or fetuses with  
83 chromosomal aberrations were excluded. Relative risks were calculated using log-linear Poisson  
84 models for congenital heart defects overall, severe congenital heart defects and for five of the  
85 most prevalent subtypes of congenital heart defects.

86 Results: Of the 547 178 pregnancies included in the cohort, 5 498 had congenital heart defects  
87 (1.0%). Risk of congenital heart defects became gradually higher with higher maternal BMI; for  
88 BMI 30-34.9 kg/m<sup>2</sup>, adjusted relative risk = 1.23 (95% confidence interval 1.12-1.36), for BMI 35-  
89 39.9 kg/m<sup>2</sup>, adjusted relative risk = 1.26 (95% confidence interval 1.09-1.46) and for BMI ≥ 40  
90 kg/m<sup>2</sup>, adjusted relative risk = 1.81 (95% confidence interval 1.50-2.15). Data was adjusted for  
91 maternal age, smoking status and year of estimated due date. The same pattern was seen for the  
92 subgroup of severe congenital heart defects. Among the atrioventricular septal defects (n = 245), a  
93 particularly strong association with maternal BMI ≥ 40 kg/m<sup>2</sup> was seen, adjusted relative risk =  
94 4.19 (95% confidence interval 2.13-7.42). 107 627 women were identified with their first and  
95 second pregnancies in the cohort. Interpregnancy BMI change was positively, albeit not  
96 statistically significant, associated with risk of congenital heart defects in the second pregnancy  
97 when adjusting for maternal age and BMI, with an adjusted relative risk = 1.27 (95% confidence  
98 interval 0.96-1.64) among persons with a BMI increase of ≥ 4 kg/m<sup>2</sup>.

99 Conclusions: When including both pre- and postnatally diagnosed congenital heart defects, this  
100 study showed a positive dose-response association between maternal BMI and risk of congenital  
101 heart defects in the offspring. However, only a non-significant trend was seen between  
102 interpregnancy BMI changes and risk of congenital heart defects in the second pregnancies.

103

104 Keywords: atrioventricular septum defect; coarctation of the aorta; epidemiological study;  
105 maternal BMI; prenatal congenital heart defects; register-based study; severe congenital heart  
106 defects; The Danish Fetal Medicine database; Tetralogy of Fallot; transposition of the great  
107 arteries; univentricular heart

## 108 **Introduction**

109 Obesity among women of reproductive age has been increasing over the last three decades.<sup>1</sup>

110 Centers for Disease Control and Prevention estimated that 40% of women aged 20-39 years old in  
111 the United States were obese (body mass index [BMI]  $\geq 30$  kg/m<sup>2</sup>) in 2017-2018.<sup>2</sup> Maternal obesity  
112 is a risk factor for adverse pregnancy outcomes as well as for long-term health consequences for  
113 both the mother and child.<sup>3,4</sup> Furthermore, maternal obesity is positively associated with risk of  
114 having a child with congenital malformations.<sup>5</sup>

115 Congenital heart defects (CHDs) remain the leading cause of infant death from congenital  
116 malformations in the United States.<sup>6</sup> Believed to be the most common congenital malformations,  
117 CHDs have a global prevalence of nine per 1000 live births with geographical differences.<sup>7</sup> The  
118 causes of CHDs are unknown in most cases, but are associated with maternal chronic conditions,  
119 viral infections and fetal exposures to teratogenic drugs.<sup>8-10</sup> Conflicting evidence of an association  
120 between maternal age and fetal CHDs persist, but a recent large European study found a positive  
121 association between both young- and older maternal age and total prevalence of CHDs.<sup>11</sup> With  
122 improvements in genetic and genomic analytical techniques an increasing number of genetic  
123 associations/causes have been identified in up to 30% of the cases.<sup>12</sup>

124 The association between maternal obesity and infants born with congenital malformations has  
125 been reported to include CHDs. However, none of the large studies have included the proportion  
126 of CHDs that are identified and terminated in pregnancy. During the last two decades, the prenatal  
127 identification of CHDs have increased dramatically, consequently, an analysis of the association  
128 between maternal risk factors and CHDs should include data on prenatally identified cases. Meta-  
129 analyses suggest a moderate association between maternal obesity (BMI  $\geq 30$  kg/m<sup>2</sup>) and CHDs in



130 the offspring with an odds ratio (OR) = 1.2 (95% confidence interval [CI] 1.1–1.2)<sup>13</sup> or an OR = 1.3  
131 (95% CI 1.2–1.4).<sup>14</sup> A recent systematic review on the topic demonstrated great heterogeneity  
132 among the studies with respect to design, exposure definition, outcome definition, choice of  
133 covariates, and only populations of Northern European or Chinese descent were examined to a  
134 reasonable extent.<sup>15</sup>

135 Some studies have found an association between maternal interpregnancy BMI changes and  
136 adverse pregnancy- and perinatal outcomes that were linearly related to the amount of weight  
137 gain.<sup>16,17</sup> So far, a few small studies suggest that this might be relevant for certain congenital  
138 malformations (spina bifida, gastroschisis and oral cleft),<sup>16,18-20</sup> however, no data is available in  
139 these studies for fetal CHDs. It is of great importance to identify any modifiable risk factors for  
140 CHDs. If weight gain, defined as interpregnancy BMI change, is associated with CHDs, this could be  
141 added to the etiology of the association and the justification of preventive initiatives as to stress  
142 weight stability, and for some women weight loss.

143 This study aims to assess the risk of fetal CHDs, severe CHDs or five of the most frequently  
144 identified subtypes of CHDs according to early-pregnancy BMI. The study population comprises all  
145 CHDs found among live births, stillbirths, abortions and terminated pregnancies in Denmark. The  
146 study also investigates if changes in maternal BMI from the beginning of the first pregnancy to the  
147 beginning of the second pregnancy were associated with risk of CHDs in the second pregnancy.

## 148 **Materials and Methods**

149 This cohort study was performed on prospectively collected data retrieved from a nationwide  
150 cohort based on The Danish Fetal Medicine Database.<sup>21</sup> The Danish Fetal Medicine Database  
151 includes data on pregnancies with prenatal screening results from all obstetric and gynecological

152 departments in Denmark from January 1, 2008.<sup>21</sup> All women in Denmark are offered a first  
153 trimester screening for chromosomal abnormalities (gestational week 12) and a second trimester  
154 anomaly scan, for which the uptake rate is high; 95% of pregnant women participate. The  
155 database does not include data on outcomes of pregnancies before the first trimester scan. The  
156 primary source of information is the local fetal medicine databases used nationwide. The Danish  
157 Fetal Medicine Database includes data on maternal characteristics including weight and height,  
158 data from ultrasound examinations and pregnancy outcomes.<sup>21</sup> Furthermore, the database  
159 includes data from other Danish registers: the Danish Cytogenetic Central Register,<sup>22</sup> the Danish  
160 National Patient Register,<sup>23</sup> and the Danish Medical Birth Register.<sup>24</sup> All Danish residents are  
161 assigned a unique personal identification number enabling linkage of data between national  
162 registers and other data sources.<sup>25</sup> In Denmark, health care is free and it is standard practice  
163 to offer genetic testing by chorionic villus sampling or amniocentesis when a CHD is diagnosed  
164 prenatally.<sup>26</sup> The prenatal detection rate of major CHD is high and the majority of parents opt for  
165 further testing.<sup>27,28</sup> A gradual transition from conventional karyotyping to chromosomal  
166 microarray was observed over the course of the study period. Postnatal genetic testing primarily  
167 by chromosomal microarray is performed in all children with syndromic suspicion. The Danish  
168 Fetal Medicine database is updated once a year with information on postnatal diagnosed  
169 congenital malformations and karyotypes.<sup>21</sup> The International Classification of Diseases, 10th  
170 revision code system (ICD-10) is used to code malformations in the fetus and in the infant.<sup>21</sup>  
171 The cohort included singleton pregnancies in Denmark with an estimated due date, from  
172 ultrasound scan, between June 1, 2008 and June 1, 2018. Each woman can have multiple  
173 pregnancies during the study period. Pregnancies with a fetus or child with a chromosomal  
174 aberration were excluded from the cohort. Only pregnant women with a registered early-

175 pregnancy weight and a height from 120 through 200 cm were included. Maternal BMI was  
176 calculated as weight in kilograms divided by the square of the height in meters ( $\text{kg}/\text{m}^2$ ) and BMI  
177 values are reported in that unit. Extreme observations defined as  $\text{BMI} < 12$  and  $\text{BMI} > 60$  were  
178 excluded to avoid registration errors.

179 We identified fetuses and infants with CHDs (Table S1) by using either the prenatal or/and the  
180 postnatal diagnoses. In all live births, postnatal CHD diagnoses were considered gold standard. The  
181 CHD diagnoses were defined by the European Surveillance of Congenital Anomalies (EUROCAT)<sup>29</sup>  
182 (Table S1) and severe CHDs (EUROCAT, Table S1). Severe CHDs include the following 17 diagnoses:  
183 truncus arteriosus, double outlet right ventricle, transposition of the great arteries (TGA),  
184 univentricular heart (UVH), atrioventricular septum defect (AVSD), Tetralogy of Fallot (ToF),  
185 pulmonary atresia, tricuspid valve stenosis, Ebstein's anomaly, hypoplastic right heart syndrome,  
186 aortic valve stenosis, mitral valve stenosis, mitral insufficiency, hypoplastic left heart syndrome,  
187 coarctation of the aorta (CoA), aortic atresia, and total anomalous pulmonary venous return.  
188 Irrespective of the number of CHD diagnoses in a particular patient, the patient was only  
189 registered once as having CHDs. Furthermore, offspring with five of the most frequent subtypes of  
190 severe CHDs were identified (Table S2). These were ranked as defined by Lytzen et al.<sup>27</sup> with the  
191 most severe first (UVH > TGA > AVSD > CoA > ToF). If offspring had combinations of these  
192 subtypes, they were only registered once with the most severe diagnosis. ICD-10 codes for severe  
193 CHDs have been validated against hospital records with very good agreement in the Danish  
194 National Patient Register.<sup>30</sup> Prenatal diagnoses of 12 severe CHDs have been shown to have a very  
195 high diagnostic precision.<sup>28</sup>

196 For the calculations of interpregnancy BMI changes, a sub-cohort including women with first and  
197 second pregnancies and more than 50 weeks between estimated due dates was compiled.  
198 Maternal height was defined as the height registered in the first pregnancy. Interpregnancy BMI  
199 changes were calculated as the difference between BMI at the beginning of the first and BMI at  
200 the beginning of the second pregnancy. Differences were categorized into six groups < -2; -2 to < -  
201 1; -1 to < 1; 1 to < 2; 2 to < 4; and  $\geq 4$  BMI units. The category -1 to < 1 was defined as stable weight  
202 and used as reference.

203 Associations between maternal BMI and offspring risk of CHDs were calculated as risk ratios (RRs)  
204 with 95% CI using log-linear Poisson regression models. The models were adjusted for maternal  
205 age (<20, 20–24, 25–29, 30–34, 35–39,  $\geq 40$  years), maternal smoking status (yes/no/stopped), and  
206 year of estimated due date (1-year groups). The model was not adjusted for potential multiple  
207 pregnancies for each woman during the study period. Associations between interpregnancy BMI  
208 changes and risk of CHDs were calculated as RRs with 95% CI using log-linear Poisson regression  
209 models. Maternal BMI in first pregnancy and maternal age at second pregnancy were considered  
210 possible confounders and were adjusted for in the multivariate model. Statistical analyses were  
211 run in R version 4.2.1. Statens Serum Institut has approval from the Danish Data Protection Agency  
212 to conduct register-based studies, and the project has been approved (journal no. 19/03354 and  
213 20/09279).

## 214 **Results**

215 The study cohort consisted of 547 178 singleton pregnancies with estimated due dates between  
216 June 1, 2008 and June 1, 2018 when pregnancies with chromosomal aberrations and missing data  
217 were excluded as detailed in Figure 1. A total of 5 498 (1.0%) offsprings had CHDs. Of these 1 227

218 were defined as severe CHDs (0.2%). Clinical and demographic data are available in Table 1.  
219 Information on parity was not registered and therefore missing in the dataset from 2008-2011  
220 corresponding to 25% of the pregnancies. The study cohort comprised 534 478 live births (97.7%),  
221 1 623 stillbirths (0.3%), 5 073 abortions or terminated pregnancies (0.9%), and 6 004 pregnancies  
222 with missing outcomes (1.1%). In total, 35% of the women had an early-pregnancy BMI  $\geq$  25, and  
223 13% were obese (BMI  $\geq$  30). The distribution of maternal BMI among the different groups and  
224 covariates can be seen in Table 1.

225 Maternal overweight was associated significantly with higher risk of CHDs in the offspring  
226 increasing with higher maternal BMI: for BMI 25-29.9, adjusted relative risk (aRR) = 1.17 (95% CI  
227 1.09-1.25), for BMI 30-34.9, aRR = 1.23 (95% CI 1.12-1.36), for BMI 35-39.9, aRR = 1.26 (95% CI  
228 1.09-1.46) and for BMI  $\geq$  40, aRR = 1.81 (95% CI 1.50-2.15) compared to women with an early-  
229 pregnancy BMI 18.5-24.9 (Table 2). Similar results were seen for maternal BMI and severe CHDs:  
230 for BMI 25-29.9, aRR = 1.20 (95% CI 1.04-1.38), for BMI 30-34.9, aRR = 1.28 (95% CI 1.04-1.56), for  
231 BMI 35-39.9, aRR = 1.47 (95% CI 1.09-1.96) and for BMI  $\geq$  40, aRR = 1.85 (95% CI 1.23-2.67)  
232 compared to women with an early-pregnancy BMI 18.5-24.9 (Table 2). A slightly higher risk of  
233 CHDs, when only including live births compared to all pregnancies, was seen for maternal BMI  $\geq$  30  
234 (aRR 1.24-1.87; data available in Table S3).

235 The proportion of CHD cases with one of the five specific CHD diagnoses were as follows:  
236 univentricular heart (UVH; 4.4%), transposition of the great arteries (TGA; 3.2%), atrioventricular  
237 septum defect (AVSD; 4.5%), coarctation of the aorta (CoA; 4.6%), and Tetralogy of Fallot (ToF;  
238 2.3%). The association between maternal BMI and these specific five CHD diagnoses are shown in

239 Figure 2. No significant associations were seen for UVH, TGA, CoA and ToF. However, maternal  
240 BMI  $\geq 30$  was associated with a significantly higher risk of AVSD in the offspring (Figure 2).  
241 The sub-cohort included 107 627 women who had a first and second consecutive singleton  
242 pregnancies between June 1, 2008 and June 1, 2018 (Table 3). Mean BMI in first pregnancy was  
243 24.9 vs. 25.8 in second pregnancy. In total, 998 had an offspring with CHDs (0.9%) in their second  
244 pregnancy. The prevalence of CHDs in the second pregnancy became higher with increased weight  
245 gain between pregnancies (0.8% to 1.3%). Increase in maternal BMI between pregnancies were  
246 significantly associated with higher risk of CHDs in second pregnancy. However, when adjusted for  
247 maternal age in the second pregnancy and maternal BMI in the first pregnancy, only a trend  
248 remained towards higher risks of any CHDs with weight gain between pregnancies (Table 3).

## 249 **Comment**

### 250 **Principal Findings**

251 When including both pre- and postnatally diagnosed CHDs, this study showed a dose-response  
252 association between high maternal BMI and risk of CHDs in the offspring. However, only a non-  
253 significant trend was seen between interpregnancy BMI changes between first and second  
254 pregnancies and risk of fetal CHDs in the second pregnancies.

### 255 **Results in the Context of What is Known**

256 This prospective nationwide cohort included 547 178 live births, stillbirths, abortions and  
257 terminated pregnancies in Denmark from 2008 to 2018 and showed that maternal overweight and  
258 obesity were significantly associated with a moderately higher risk of CHDs (aRR = 1.17-1.81) and  
259 severe CHDs (aRR = 1.20-1.85) in the offspring compared to women with a BMI in the normal

260 range (BMI 18.5-24.9). The study validates previous findings of a positive association between high  
261 maternal BMI and risk of CHDs in the offspring<sup>13,14,31,32</sup> and thereby rejects any hypothesis of this  
262 association to be caused by lower prenatal detection rates of CHDs in pregnant women with  
263 obesity. Most other studies have been limited to live births.<sup>15,31</sup> A large nationwide Swedish study  
264 with two million live born children found a positive association between high maternal BMI and  
265 CHDs (BMI 30-34.9: OR = 1.2, 95% CI 1.2–1.3; BMI ≥ 40: OR = 1.6, 95% CI 1.4–1.8).<sup>31</sup> When  
266 restricting our analysis to live births (Table S3), we found significant associations of a similar  
267 magnitude between maternal BMI ≥ 25 and CHDs. Results from five specific subtypes of CHDs  
268 (UVH, TGA, AVSD, CoA and ToF) showed no significant association with maternal BMI except for  
269 AVSD (Figure 2), which was significantly associated with increased risks when maternal BMI ≥ 30  
270 (BMI 30 to ≥ 40: aRR = 1.65-4.19). Persson et al. found a non-significant trend between maternal  
271 BMI and AVSD in women with BMI ≥ 30,<sup>5</sup> and the same pattern was observed in other  
272 studies.<sup>9,33,34</sup> The lack of statistical significance in other studies might be due to few cases in each  
273 BMI group or different study designs. We examined the interpregnancy weight changes between  
274 the first and second pregnancies in 107 627 women and found a trend towards higher risks of  
275 CHDs in second pregnancies preceded by a substantial BMI gain but this was not significant when  
276 data was adjusted for maternal BMI in first pregnancy and maternal age in second pregnancy  
277 (Table 3) as a result of the correlation between maternal BMI and interpregnancy weight changes.  
278 The investigations of the association between interpregnancy weight changes and risk of fetal  
279 CHDs are sparse.<sup>16</sup> A few studies have looked at other congenital malformations and found a RR =  
280 2.3 for isolated cleft palate when maternal BMI increased ≥ 3 units,<sup>20</sup> a positive association  
281 between spina bifida and interpregnancy BMI gain,<sup>18</sup> and a significant decrease in OR = 0.62 (95%  
282 CI 0.42-0.94) for gastroschisis when maternal BMI increased with ≥ 3 units.<sup>19</sup>

## 283 **Clinical Implications**

284 Lifestyle interventions to reduce risk of fetal CHDs have been suggested to be introduced before or  
285 between pregnancies.<sup>35</sup> Although our results only indicate a trend between interpregnancy weight  
286 changes and risk of CHDs, it does not dismiss a positive effect of weight reduction in women with  
287 obesity before pregnancy. In a setting with pre-pregnancy counseling, it is still important to advise  
288 women about the importance of BMI as a risk factor for congenital malformations,<sup>5</sup> obstetric and  
289 perinatal complications.<sup>3,4</sup>

## 290 **Research Implications**

291 Prenatal detection rates of congenital malformations decreases with increasing maternal BMI  
292 since image quality is lower in women with obesity.<sup>36,37</sup> Consequently, studies only including live  
293 births could be biased towards a higher postnatal prevalence of CHDs in women with obesity if  
294 severe fetal CHDs were not diagnosed and possibly terminated during pregnancy (Table 1). Thus,  
295 this phenomenon may at least partly explain a positive association between high BMI and  
296 prevalence of CHDs in live borns.<sup>5</sup> Prenatal detection rates of CHDs have improved substantially in  
297 the last decades, and in countries with prenatal screening with high detection rate of CHDs as in  
298 Denmark,<sup>28</sup> it is more important to include terminated pregnancies in prevalence and association  
299 studies as the rate of terminated pregnancies with the most severe CHDs likely will be higher as  
300 seen in Table 1.

301 This study confirms the association between high maternal BMI and risk of fetal CHDs. Knowledge  
302 about the etiology is still limited<sup>35</sup> and future research should focus on combinations of other  
303 related maternal metabolic disorders linked to insulin resistance as suggested in a recent review.<sup>15</sup>

## 304 **Strengths and Limitations**



305 The strength of this study is the large size of the cohort and prospectively, nationwide data  
306 collection including prenatal information. Some limitation must be considered. The database did  
307 not include data on pregestational diabetes, which is known to be strongly associated with CHDs,  
308 and therefore this confounder was not included as a covariate in the analyses.<sup>15,38</sup> Persson et al.  
309 excluded all women with pregestational diabetes and found a moderate association similar to the  
310 results of the present study.<sup>31</sup> Nor did the data include information about family history of CHDs,<sup>39</sup>  
311 maternal infections or teratogenic medicine intake in pregnancy that have been associated with  
312 higher risk of CHDs.<sup>8</sup> Since the study draws conclusions from register data, there is a risk of  
313 reporting bias and all CHD diagnoses are not validated against hospital records.

#### 314 **Conclusions**

315 High maternal BMI is associated with risk of fetal CHDs, and while substantial weight gain between  
316 pregnancies may impact the risk, it does not appear to have a significant effect on it.

317

#### 318 **Acknowledgements**

319 The study group wishes to thank sonographers and medical doctors, who have and continuously  
320 are collecting data for the Danish Fetal Medicine Database.

321 An earlier version of the article is available at a preprint server, MedRxiv  
322 (<https://medrxiv.org/cgi/content/short/2023.02.12.23285811v1>).

323

#### 324 **Glossary**

- 325 AVSD, atrioventricular septum defect
- 326 CHDs, congenital heart defects
- 327 CoA, coarctation of the aorta
- 328 EUROCAT, European Surveillance of Congenital Anomalies
- 329 TGA, transposition of the great arteries
- 330 ToF, Tetralogy of Fallot
- 331 UVH, univentricular heart
- 332

333 **References**

- 334 1. Poston L, Caleyachetty R, Cnattingius S, et al. Preconceptional and maternal obesity:  
335 epidemiology and health consequences. *Lancet Diabetes Endocrinol* 2016;4:1025-36.
- 336 2. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity  
337 Among Adults: United States, 2017-2018. *NCHS Data Brief* 2020;(360):1-8.
- 338 3. Godfrey KM, Reynolds RM, Prescott SL, et al. Influence of maternal obesity on the  
339 long-term health of offspring. *Lancet Diabetes Endocrinol* 2017;5:53-64.
- 340 4. Catalano PM, Shankar K. Obesity and pregnancy: mechanisms of short term and long  
341 term adverse consequences for mother and child. *BMJ* 2017;356:j1.
- 342 5. Persson M, Cnattingius S, Villamor E, et al. Risk of major congenital malformations in  
343 relation to maternal overweight and obesity severity: cohort study of 1.2 million singletons. *BMJ*  
344 2017;357:j2563.
- 345 6. Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics-2018  
346 Update: A Report From the American Heart Association. *Circulation* 2018;137:e67-e492.
- 347 7. Liu Y, Chen S, Zuhlke L, et al. Global birth prevalence of congenital heart defects  
348 1970-2017: updated systematic review and meta-analysis of 260 studies. *Int J Epidemiol*  
349 2019;48:455-63.
- 350 8. Jenkins KJ, Correa A, Feinstein JA, et al. Noninherited risk factors and congenital  
351 cardiovascular defects: current knowledge: a scientific statement from the American Heart  
352 Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy  
353 of Pediatrics. *Circulation* 2007;115:2995-3014.

- 354 9. Liu S, Joseph KS, Lisonkova S, et al. Association between maternal chronic conditions  
355 and congenital heart defects: a population-based cohort study. *Circulation* 2013;128:583-9.
- 356 10. Ye Z, Wang L, Yang T, et al. Maternal Viral Infection and Risk of Fetal Congenital Heart  
357 Diseases: A Meta-Analysis of Observational Studies. *J Am Heart Assoc* 2019;8:e011264.
- 358 11. Mamasoula C, Bigirumurame T, Chadwick T, et al. Maternal age and the prevalence  
359 of congenital heart defects in Europe, 1995-2015: A register-based study. *Birth Defects Res*  
360 2023;115:583-94.
- 361 12. Pierpont ME, Brueckner M, Chung WK, et al. Genetic Basis for Congenital Heart  
362 Disease: Revisited: A Scientific Statement From the American Heart Association. *Circulation*  
363 2018;138:e653-e711.
- 364 13. Zhu Y, Chen Y, Feng Y, Yu D, Mo X. Association between maternal body mass index  
365 and congenital heart defects in infants: A meta-analysis. *Congenit Heart Dis* 2018;13:271-81.
- 366 14. Zheng Z, Yang T, Chen L, et al. Increased maternal Body Mass Index is associated with  
367 congenital heart defects: An updated meta-analysis of observational studies. *Int J Cardiol*  
368 2018;273:112-20.
- 369 15. Hedermann G, Hedley PL, Thagaard IN, et al. Maternal obesity and metabolic  
370 disorders associate with congenital heart defects in the offspring: A systematic review. *PLoS One*  
371 2021;16:e0252343.
- 372 16. Bogaerts A, Van den Bergh BRH, Ameye L, et al. Interpregnancy weight change and  
373 risk for adverse perinatal outcome. *Obstet Gynecol* 2013;122:999-1009.
- 374 17. Villamor E, Cnattingius S. Interpregnancy weight change and risk of adverse  
375 pregnancy outcomes: a population-based study. *The Lancet* 2006;368:1164-70.

- 376 18. Benjamin RH, Ethen MK, Canfield MA, Hua F, Mitchell LE. Association of  
377 interpregnancy change in body mass index and spina bifida. *Birth Defects Res* 2019;111:1389-98.
- 378 19. Benjamin RH, Ethen MK, Canfield MA, Mitchell LE. Change in prepregnancy body  
379 mass index and gastroschisis. *Ann Epidemiol* 2020;41:21-7.
- 380 20. Villamor E, Sparen P, Cnattingius S. Risk of oral clefts in relation to prepregnancy  
381 weight change and interpregnancy interval. *Am J Epidemiol* 2008;167:1305-11.
- 382 21. Ekelund CK, Kopp TI, Tabor A, Petersen OB. The Danish Fetal Medicine database. *Clin*  
383 *Epidemiol* 2016;8:479-83.
- 384 22. Videbech P, Nielsen J. Electronic data processing in the Danish cytogenetic central  
385 register and EDP problems of registers in general. *Clin Genet* 1979;15:137-46.
- 386 23. Lyng E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J*  
387 *Public Health* 2011;39:30-3.
- 388 24. Knudsen LB, Olsen J. The Danish Medical Birth Registry. *Dan Med Bull* 1998;45:320-3.
- 389 25. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration  
390 System. A cohort of eight million persons. *Dan Med Bull* 2006;53:441-9.
- 391 26. Vedel C, Hjortshoj TD, Jorgensen DS, et al. Prevalence of chromosomal disorders in  
392 cases with congenital heart defect: registry-based study from Denmark between 2008 and 2018.  
393 *Ultrasound Obstet Gynecol* 2023;61:40-48.
- 394 27. Lytzen R, Vejlstrup N, Bjerre J, et al. Live-Born Major Congenital Heart Disease in  
395 Denmark: Incidence, Detection Rate, and Termination of Pregnancy Rate From 1996 to 2013.  
396 *JAMA Cardiology* 2018;3:829-37.
- 397 28. Vedel C, Tabor A, Jorgensen FS, et al. Prenatal detection rate of major congenital  
398 heart defects in Copenhagen from 2015 to 2018. *Ultrasound Obstet Gynecol* 2021;58:324-5.

- 399 29. Greenlees R, Neville A, Addor MC, et al. Paper 6: EUROCAT member registries:  
400 organization and activities. *Birth Defects Res A Clin Mol Teratol* 2011;91 Suppl 1:S51-S100.
- 401 30. Agergaard P, Hebert A, Bjerre J, Sorensen KM, Olesen C, Ostergaard JR. Children  
402 diagnosed with congenital cardiac malformations at the national university departments of  
403 pediatric cardiology: positive predictive values of data in the Danish National Patient Registry. *Clin  
404 Epidemiol* 2011;3:61-6.
- 405 31. Persson M, Razaz N, Edstedt Bonamy AK, Villamor E, Cnattingius S. Maternal  
406 Overweight and Obesity and Risk of Congenital Heart Defects. *J Am Coll Cardiol* 2019;73:44-53.
- 407 32. Cai GJ, Sun XX, Zhang L, Hong Q. Association between maternal body mass index and  
408 congenital heart defects in offspring: a systematic review. *Am J Obstet Gynecol* 2014;211:91-117.
- 409 33. Block SR, Watkins SM, Salemi JL, et al. Maternal pre-pregnancy body mass index and  
410 risk of selected birth defects: evidence of a dose-response relationship. *Paediatr Perinat Epidemiol*  
411 2013;27:521-31.
- 412 34. Agopian AJ, Moulik M, Gupta-Malhotra M, Marengo LK, Mitchell LE. Descriptive  
413 epidemiology of non-syndromic complete atrioventricular canal defects. *Paediatr Perinat  
414 Epidemiol* 2012;26:515-24.
- 415 35. Helle E, Priest JR. Maternal Obesity and Diabetes Mellitus as Risk Factors for  
416 Congenital Heart Disease in the Offspring. *J Am Heart Assoc* 2020;9:e011541.
- 417 36. Best KE, Tennant PW, Bell R, Rankin J. Impact of maternal body mass index on the  
418 antenatal detection of congenital anomalies. *BJOG* 2012;119:1503-11.
- 419 37. Uhden M, Knippel AJ, Stressig R, et al. Impact of maternal obesity and maternal  
420 overweight on the detection rate of fetal heart defects and the image quality of prenatal  
421 echocardiography. *Ultraschall Med* 2011;32 Suppl 2:E108-14.

- 422 38. Oyen N, Diaz LJ, Leirgul E, et al. Prepregnancy Diabetes and Offspring Risk of  
423 Congenital Heart Disease: A Nationwide Cohort Study. *Circulation* 2016;133:2243-53.
- 424 39. Brodwall K, Greve G, Leirgul E, Tell GS, Vollset SE, Oyen N. Recurrence of congenital  
425 heart defects among siblings-a nationwide study. *Am J Med Genet A* 2017;173:1575-85.
- 426

427 **Tables**

428 Table 1. *Maternal, pregnancy and offspring characteristics in singleton pregnancies in Denmark*

429 *2008-2018.*

Characteristics	Pregnancies with congenital heart defects (EUROCAT), n = 5 498	Severe congenital heart defects (EUROCAT), n = 1 227	Pregnancies without congenital heart defects, n = 541 680
Body mass index, kg/m <sup>2</sup>	n (%)	n (%)	n (%)
< 18.5	371 (6.8)	79 (6.4)	35 792 (6.6)
18.5-<25	2 968 (54.0)	656 (53.5)	318 498 (58.8)
25-<30	1 299 (23.6)	289 (23.6)	117 372 (21.7)
30-<35	531 (9.7)	123 (10.0)	45 927 (8.5)
35-<40	203 (3.7)	53 (4.3)	16 633 (3.1)
≥40	126 (2.3)	27 (2.2)	7 458 (1.4)
Maternal age at conception, years			
<20	125 (2.3)	31 (2.5)	9 371 (1.7)
20-24	773 (14.1)	174 (14.2)	70 701 (13.1)
25-29	1 871 (34.0)	404 (32.9)	184 442 (34.1)
30-34	1 745 (31.7)	403 (32.8)	181 879 (33.6)
35-39	843 (15.3)	188 (15.3)	81 370 (15.0)
≥40	141 (2.6)	27 (2.2)	13 917 (2.8)
Ethnicity			
Caucasian	5 056 (92.0)	1 134 (92.4)	492 378 (90.9)
Non-Caucasian	315 (5.7)	73 (5.9)	35 846 (6.6)
Missing	127 (2.3)	20 (1.6)	13 456 (2.5)
Smoking status			
No	4 724 (85.9)	1 080 (88.0)	478 823 (88.4)
Yes	627 (11.4)	115 (9.4)	50 238 (9.3)
Stopped	92 (1.7)	20 (1.6)	8 765 (1.6)
Missing	55 (1.0)	12 (1.0)	3 854 (0.7)



Conception			
Spontaneous	4 950 (90.0)	1 117 (91.0)	497 936 (91.9)
Assisted	463 (8.4)	97 (7.9)	36 516 (6.8)
Unknown	85 (1.5)	13 (1.1)	7 228 (1.3)
Parity			
0	2 046 (37.2)	416 (33.9)	181 065 (33.4)
1	1 571 (28.6)	367 (29.9)	153 479 (28.3)
2	540 (9.8)	133 (10.8)	53 959 (10.0)
≥3	203 (3.7)	38 (3.1)	16 653 (3.1)
Missing	1 138 (20.7)	273 (22.2)	136 524 (25.2)
Year of estimated due date			
2008	216 (3.9)	57 (4.6)	25 266 (4.7)
2009	477 (8.7)	126 (10.3)	56 468 (10.4)
2010	550 (10.0)	131 (10.7)	57 687 (10.7)
2011	528 (9.7)	120 (9.8)	53 630 (9.9)
2012	534 (9.7)	137 (11.2)	53 512 (9.9)
2013	508 (9.2)	120 (9.8)	51 331 (9.5)
2014	590 (10.7)	141 (11.5)	52 609 (9.7)
2015	642 (11.7)	137 (11.2)	54 215 (10.0)
2016	607 (11.0)	110 (9.0)	57 402 (10.6)
2017	543 (9.9)	101 (8.2)	56 569 (10.4)
2018	303 (5.5)	47 (3.8)	22 991 (4.2)
Outcome pregnancy			
Live births	5 187 (94.3)	1 011 (82.4)	529 291 (97.7)
Stillbirths	41 (0.7)	26 (2.1)	1 582 (0.3)
Abortions and terminated pregnancies after gestational week 12	245 (4.5)	175 (14.3)	4 828 (0.9)
Missing	25 (0.5)	15 (1.2)	5 979 (1.1)
Offspring sex			

Male	2 771 (50.4)	624 (50.9)	271 571 (50.1)
Female	2 416 (43.9)	387 (31.5)	257 720 (47.6)
Unknown	311 (5.7)	216 (17.6)	12 389 (2.3)

430

431 Abbreviations: EUROCAT, European Surveillance of Congenital Anomalies (diagnoses listed in Table

432 S1)

433 Table 2. *Relative risks of congenital heart defects by maternal BMI in 547 178 offsprings (live*  
 434 *births, stillbirths, abortions and terminated pregnancies), Denmark 2008-2018.*

Maternal BMI (kg/m <sup>2</sup> )	No CHDs	CHDs					Severe CHDs				
	n = 541 680	n = 5 498					n = 1 227				
	Total	Total	Crude RR	95% CI	aRR*	95% CI	Total	Crude RR	95% CI	aRR*	95% CI
< 18.5	35 800	371	1.11	1.00-1.24	1.07	0.95-1.19	79	1.07	0.84-1.34	1.02	0.79-1.30
18.5 - 24.9	318 489	2 968	1.00	ref	1.00	ref	656	1.00	ref	1.00	ref
25 - 29.9	117 373	1 299	1.19	1.11-1.27	1.17	1.09-1.25	289	1.19	1.04-1.37	1.20	1.04-1.38
30 - 34.9	45 926	531	1.24	1.13-1.36	1.23	1.12-1.36	123	1.30	1.07-1.57	1.28	1.04-1.56
35 - 39.9	16 635	203	1.31	1.13-1.50	1.26	1.09-1.46	53	1.55	1.15-2.02	1.47	1.09-1.96
≥ 40	7 457	126	1.80	1.50-2.14	1.81	1.50-2.15	27	1.76	1.17-2.52	1.85	1.23-2.67

435

436 Abbreviations: aRR, adjusted relative risk; BMI, body mass index; CHD, congenital heart defects; CI,  
 437 confidence interval; RR, relative risk.

438 \*aRR adjusted for maternal age at conception, smoking status (yes/no/stopped) and year of  
 439 estimated due date comparing CHD risk in women with early-pregnancy BMI < 18.5 kg/m<sup>2</sup> or BMI  
 440 ≥ 25 kg/m<sup>2</sup> with women with early-pregnancy BMI in the normal range (BMI 18.5-24.9 kg/m<sup>2</sup>).

441

442 Table 3. *Relative risks of congenital heart defects in second pregnancy by interpregnancy maternal*  
 443 *BMI changes in 107 627 women with two consecutive singleton pregnancies, Denmark 2008-2018.*

BMI change from 1st to 2nd pregnancy		1st pregnancy	2nd pregnancy	Risk of CHDs in 2nd pregnancy					
Units, kg/m <sup>2</sup>	No. of women with 1st and 2nd pregnancy (%)	Mean BMI	Mean BMI	n/N	Prevalence of CHDs (%)	Crude RR	95% CI	aRR*	95% CI
<-2	5 941 (5.5)	27.3	24.3	50/5 891	0.8	0.95	0.70-1.26	0.84	0.61-1.12
-2 to <-1	11 154 (10.4)	24.2	22.8	90/11 064	0.8	0.91	0.72-1.14	0.88	0.70-1.09
-1 to <-1	54 154 (50.3)	22.8	22.9	479/53 675	0.9	1.00	ref	1.00	ref
1 to <-2	16 940 (15.7)	23.8	25.2	156/16 784	0.9	1.04	0.87-1.24	1.01	0.84-1.21
2 to <-4	14 010 (13.0)	25.0	27.8	155/13 855	1.1	1.25	1.04-1.50	1.17	0.97-1.40
≥ 4	5 428 (5.0)	26.3	31.4	68/5 360	1.3	1.42	1.09-1.81	1.27	0.96-1.64
Total	107 627	24.9	25.8	998/106 629	1.0				

444

445 Abbreviations: aRR, adjusted relative risk; BMI, body mass index; CHDs, congenital heart defects;  
 446 CI, confidence interval; n, number of women with their first pregnancy without CHDs and second  
 447 pregnancy with CHDs in the offspring; N, number of women with first and second pregnancies  
 448 without CHDs; RR, relative risk.

449 \*aRR adjusted for maternal age at conception at second pregnancy and early-pregnancy BMI at  
 450 1st pregnancy.

451

452 **Figure Legends**

453 Figure 1. *Flowchart.*

454 Abbreviations: BMI, body mass index; CHDs, congenital heart defects

455

456 Figure 2. *Crude relative risks for five subtypes of congenital heart defects by maternal BMI,*  
457 *singleton pregnancies in Denmark 2008-2018.*

458 Body mass index 18.5-24.9 kg/m<sup>2</sup> was considered as the normal range and used as a reference.

459 Abbreviations: CHDs, congenital heart defects; CI, confidence interval; RR, relative risk; N, number  
460 of events



Pregnancies identified from the Danish Fetal Medicine Database, 2008 - 2018:

622 332

Singleton pregnancies with an estimated due date between June 1, 2008 - June 1, 2018 included in the study cohort:

547 178

(CHDs: 5 498; severe CHDs: 1 227)



Sub-cohort: Singleton pregnancies with their first and second pregnancies

107 627

(CHDs: 998)



75 154 excluded

- 67 duplicates (pregnancies with estimated due date <30 days apart in same woman were collapsed)
- 14 097 multiple pregnancies
- 35 140 with estimated due date before or after study period
- 5 226 pregnancies with a fetus or child with chromosomal anomalies
- 20 518 with missing height or weight data
- 49 women with a height below 120 cm or above 200 cm
- 57 women with a BMI < 12 or > 60 kg/m<sup>2</sup>



**Body mass index**


**N**

**RR**

**95% CI**

Univentricular heart

< 18.5	12	1.25	0.73-2.39
18.5 - 24.9	10	1.00	0.49-2.10
25 - 29.9	5	1.40	0.78-2.74
30 - 34.9	26	1.69	0.87-3.47
35 - 39.9	10	1.79	0.76-4.16
≥ 40	3	1.26	0.29-3.96




Transposition of the great arteries

< 18.5	11	1.00	0.56-1.98
18.5 - 24.9	98	1.00	0.67-1.46
25 - 29.9	45	1.25	0.67-2.54
30 - 34.9	14	0.99	0.45-2.24
35 - 39.9	6	1.17	0.40-3.08
≥ 40	0		



Atrioventricular septal defects

< 18.5	16	1.21	0.69-1.97
18.5 - 24.9	118	1.00	0.72-1.39
25 - 29.9	58	1.33	0.97-1.82
30 - 34.9	28	1.65	1.07-2.44
35 - 39.9	14	2.27	1.25-3.81
≥ 40	11	4.17	2.12-7.39



Coactation of the aorta

< 18.5	14	0.94	0.52-1.57
18.5 - 24.9	133	1.00	0.72-1.39
25 - 29.9	65	1.33	0.98-1.78
30 - 34.9	23	1.20	0.75-1.83
35 - 39.9	9	1.30	0.61-2.40
≥ 40	7	2.36	0.998-4.67



Tetralogy of Fallot

< 18.5	10	1.24	0.60-2.28
18.5 - 24.9	72	1.00	0.72-1.39
25 - 29.9	24	0.90	0.56-1.41
30 - 34.9	13	1.25	0.66-2.18
35 - 39.9	8	2.13	0.94-4.15
≥ 40	2	1.25	0.20-3.96



Ratios

medRxiv preprint doi: <https://doi.org/10.1101/2023.02.12.23285811>; this version posted May 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.